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Abstract 
Background: Malignant glioma is the 
most common primary brain tumour in 
adults. More and more studies are focused 
on the role of surgery in prolonged median 
of survival and survival at two years. The 
purpose of this study is to add some 
arguments in favour of radical surgery in 
malignant glioma. 
Material and Methods: The study is based 
433 cases of high grade cerebral glioma 
operated between 01.01.2000-31.12.2009 at 
the Department of Neurosurgery, Cluj 
County Emergency Hospital. We analyzed 
age, gender, type and duration of 
symptoms, type of surgery, pathological 
diagnosis and the correlation of these 
factors with overall survival. Data for long 
term follow up were available for 266 
patients. 
Results: The results shows, according to 
their histological features, the fallowing 
dispersions: astrocitomas grade III (28%), 
glioblastoma multiforme (64%), high grade 
oligodendrogliomas (5%) and high grade 
ependimomas (3%). The global survival 
rate was 47 % at 12 months, 26,3% at 18 
months and 16,7% at 24 months.  The age 
and type of surgery are prognostic factors 
that significantly influenced the survival at 
12, 18 and 24 months (9,3 months age <65 
years versus 7,1 months age >65 years; 9,2 
months GTR versus 6,4 months STR-at 12 
months monitoring; 11,7 months age <65 
versus 7,7 months age >65; 11,5 months 
GTR versus 7,1 months STR-at 18 months 
monitoring; 12,8 months age <65 versus 8 
months age >65; 12,6 months GTR versus 
7,5 months STR –at 24 months 
monitoring). 
Conclusions: Our study shows that long 
term postoperative outcome after radical 
surgical resection are better than the results 
of either partial resection or simple biopsy; 
in terms of duration of survival (the 
difference of mean survival at 12, 18 and 24 
months monitoring was 2,8 months, 4,4 
months and 5,1 months respectively in 
favour of patients with gross total removal) .  
Keywords: anaplastic astrocitoma, 
anaplastic ependymoma, glioblastoma 
multiforme, gross total removal (GTR), high 
grade glioma, malignant oligodendroglioma, 
subtotal removal (STR). 
Introduction 
High grade gliomas are aggressive 
cancers. The World Health Organization 
grading system recognizes grade III and 
grade IV primary brain tumors of astrocytic, 
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oligodendroglial or mixed lineage. Despite 
advances in surgical techniques, and 
improvement in radiation treatment and 
chemotherapy, the median survival of these 
patients has changed little over the last 
decades. 
Identification of these tumours is usually 
easy by symptoms such as headaches, 
seizures or focal weakness or numbness, 
with imaging findings of an enhancing mass 
lesion. There are two major aspects of 
gliomas biology that contributes to its poor 
prognosis: the formation of new blood 
vessels through the process of angiogenesis 
and the invasion of glioma cells. The most 
severe form, glioblastoma multiforme, has a 
marked and diffuse infiltration through the 
normal brain parenchyma. Health-related 
quality of life of these patients has always 
been poor. Patients with a presumed 
primary brain tumour from clinical 
examination and radiological investigation 
have two initial surgical management 
options: biopsy or resection [25,26]. 
The goals of surgery for malignant 
glioma, as postulated by Shapiro [28], are as 
follow: 
(1) The establishment of a histological 
diagnosis. 
(2) Tumor cytoreduction for: 
(a) Improvement in neurological status 
by reduction of increased intracranial 
pressure, 
and (b) Possible change in tumor 
kinetics. 
In the recent EORTC trial [32] surgery 
seems to have no prognostic role 
concerning the survival rate. Latest studies 
are focused on the role of surgery in 
prolonged median of survival and survival 
at two years. The purpose of this study is to 
add some arguments in favour of surgery 
and especially of the radical surgery in 
malignant gliomas. 
Patients and methods 
This is a retrospective study of a single 
centre, single surgeon and represents the 
last ten years of the senior author. The 
study is based on 433 cases of high grade 
cerebral gliomas operated between 
01.01.2000 and 31.12.2009. at the 
Neurosurgical Department of Cluj County 
Emergency Hospital. Patients considered 
for the study were adults and children aged 
from 6 to 82 years old with the initial 
diagnosis of a malignant glioma. All the 
tumours were operated and gross total 
removal was the goal in all of the cases. The 
extent of surgery was reported by the 
neurosurgeon as partial or total removal, 
and confirmed on enhanced CT or MRI in 
the first 24-48 postoperative hours. The 
tumours were histological proven high 
grade gliomas.  Data for long term follow 
up were available for 266 patients. 
The following statistic methods have 
been used for group description: 
- Descriptive: the distribution value 
(mean ± standard deviation, confidence 
interval, min/max values, contingency 
tables and frequencies. 
- Analytical: the survival analysis and the 
disease free interval depending on age, 
pathological diagnostic, surgical 
procedure/resection type through Kaplan-
Meier method and the evaluation of a 
difference of survival existence between 
groups through log-rank test. 
The group of 266 patients have been 
split for the analysis of survival from 
surgery to 12, 18 and 24 months as it 
follows: 
- for observing the disease free interval at 
12 months all the 266 patients were 
included in the group 
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- for observing the disease free interval at 
18 and 24 months 228 patients were 
included (patients operated in 2009 have 
been excluded).  
All analyses were done with SPSS. 
Results 
Between the 1st t of January 2000 and 
the 31st of  December 2009, 433 malignant 
glioma have been operated. From all the 
cerebral tumour cases operated in this 
period (1861 cases) malignant gliomas 
represent 23.26%. In this period the 
temporal distribution of cases varied, the 
peaks being present in 2005 (79 cases out of 
238 operated tumours) (Figure 1) 
The patients were aged between 6 and 
82 years old. Most of the malignant glioma 
cases have been recorded in the fifth 
decade. 
From pathological point of view the 
glioblastoma multiforme was met in most 
of the cases (64%), followed by anaplastic 
astrocytoma (28%). The malignant 
oligodendroglioma and anaplastic 
ependymoma were met in 5%, 3% 
respectively. 
The most frequent symptom of the 
patients while they were admitted in our 
hospital was the increased intracranial 
pressure (ICP) (78%) followed by focal 
weakness, seizures (18.9%), and aphasia 
(11.5%). The interval between the debut of 
symptoms and admission in the hospital was 
one month for 39% of cases. An evolution of 
symptoms longer than 6 months has been 
met for 12% cases (Figure 3). 
The anaplastic astrocytoma have been 
diagnosed in 123 cases (28% of all the 
malignant glioma). Having males as 
majority (62%) and the peak incidence 
between 40-49, the total removal has been 
reached in 83, 10% of the cases. 
 
0
50
100
150
200
250
300
350
2000 2002 2004 2006 2008
Temporal distribution of cases
Cerebral tumors
High grade gliomas
 
Figure 1 Distributions of cases  
in the studied interval 
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Figure 2 Pathological distribution of malignant 
gliomas in the present study 
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Figure 3 Interval between onset of symptoms and 
admission 
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Peak age is in the fourth decade
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Figure 4 Gender and age distribution of Anaplastic 
Astrocitoma cases 
 
The lobar localization of the tumour was 
met in 61.4% (Figure 5.) of the cases, and in 
30.1% of the cases it was multilobar. The 
posterior fossa localisations and the 
intraverticular one were met at 6%, and 
2.5% respectively. 
The glioblastoma multiforme was met in 
276 cases (64% from all the malignant 
tumours). The sex distribution has shown a 
majority of males (55.5%). Unlike the 
anaplastic astrocitoma the most affected ages 
were between 50-59 (100 cases)(Figure 6). 
The gross total removal has been 
obtained in 87,5% cases. The lobar 
localization has been considered as majority 
in this case (58,6%), the glioblastoma 
multiforme with multilobar localization 
being met in 36,8% of the cases. There 
were descriptions of the localizations at the 
callosal (1,8%) (Figure 7), posterior fossa 
(1,4%) and ventricles (1,4%). 
The malignant oligodendrogliomas and 
anaplastic ependymomas were met in 5%, 
3% respectively. In both situations there 
have been a male majority and the most 
affected was the fifth decade of life. The 
total removal was reached in most of cases. 
The global survival rate for 266 patients 
included in our study was 47 % at 12 
months, 26,3% at 18 months and 16,7% at 
24 months. (Table 1) 
 
 
 
 
Figure 5 Preoperative enhanced MRI and 
postoperative contrasted CT scan of a lobar 
anaplastic astrocytoma 
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Figure 6 Age distribution of Glioblastoma cases 
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TABLE 1 
Overall survival at 12, 18 and 24 months 
Disease free 
interval 
Number of 
patients  
Global survival rate Survival mean rate 
(months) 
Survival median 
rate (months) 
12 months 266 47% 8,87 months 
CI-95%: 8,41-9,43 
11  
18 months 
 
228 26,3% 10,96 months  
CI-95%: 10,20-11,72 
11   
CI-95%:  
9,91-12,08 
24 months  
 
228 16,7% 11,96 months  
CI-95%: 11,01-12,91 
11 
 
TABLE 2 
Disease free interval regarding the age, type of surgery and pathological findings 
Disease free 
interval 
Log Rank  
(Mantel-Cox) 
factor: age 
 (<65 years/ 
≥65 years) 
Log Rank 
 (Mantel-Cox) factor:  
type of surgery (gross 
total removal/subtotal 
removal) 
Log Rank 
 (Mantel-Cox) 
factor:  
histopatholgical 
diagnosis  
Log Rank 
 (Mantel-Cox) 
factor:  
gender 
12 months 0,000 0,000 0,090 0,296 
18 months 0,000 0,000 0,122 0,836 
24 months 0,000 0,000 0,031 0,756 
 
The age and type of surgery are 
prognostic factors that significantly 
influenced the survival at 12, 18 and 24 
months, meanwhile the pathological 
diagnostic  significantly  influenced the 
survival only at 24 months (Table 2) 
 
   
 
 
Figure 7 Preoperative enhanced MRI and 
postoperative CT scan of a completely removed 
Glioblastoma Multiforme of corpus callosum 
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From all 266 cases, the gross total 
removal (GTR) was reached in 229 
patients, while the subtotal removal (STR) 
of tumours was performed in 37 cases. 
There has been a significant difference 
between expected frequencies and the 
observed ones in resection type that concerns 
survival. At 12 months monitoring, the 
survival was around 9,2 months in patients 
with GTR, with a confidence interval 
between 8,7 and 9,7, meanwhile in the STR 
group the survival mean was 6,4 months, 
with a confidence interval of 95% from 5,2 to 
7,7. (Table 3, Figure 8) 
 
TABLE 3  
Mean survival time at 12 months monitoring 
in patients with GTR and STR respectively 
Type of 
surgery 
Mean(a) 
  Estimate Std. Error 95% Confidence Interval 
      Lower 
Bound 
Upper 
Bound 
Gross total 
removal 
9,263 ,244 8,784 9,741 
Subtotal 
removal 
6,478 ,640 5,223 7,734 
Overall 8,875 ,236 8,413 9,337 
 
 
Figure 8 Type of resection as a prognostic factor at 
12 months monitoring 
Similar findings are found at 18 months 
interval monitoring , the survival mean for 
patients with GTR has been of 11.5 months 
(with a confidence interval of 95% from 
10,7 to 12,4), significantly higher than 
survival rate for STR group (7,1 months, 
with confidence from 5,5 to 8,7, p<0,005) 
(Table 4, Figure 9). 
The survival monitoring at 24 months 
also highlighted a significant difference of 
survival between GTR and STR groups 
(p< 0,005). The survival mean at GTR 
group was of 12,6 months, compared to the 
7,5 months one for the STR group (Table 
8, Figure 4). 
 
Figure 9 Mean and median survival time and 
survival graphic at 18 months depending on the type 
of surgery 
 
Figure 10 Mean and median survival time at 24 
months depending on the type of surgery 
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TABLE 4 
Mean survival time for 18 months monitoring 
Type of 
surgery 
Mean(a) Median 
  Estimate Std. 
Error 
95% Confidence 
Interval 
Estimate Std. 
Error 
95% Confidence 
Interval 
      Lower 
Bound 
Upper 
Bound 
    Lower 
Bound 
Upper 
Bound 
Gross 
total 
removal 
11,592 ,414 10,780 12,405 12,500 ,673 11,182 13,818 
Subtotal 
removal 
7,133 ,822 5,522 8,744 6,000 ,849 4,337 7,663 
Overall 10,966 ,388 10,205 11,727 11,000 ,552 9,917 12,083 
 
TABLE 5 
Mean survival time at 24 months monitoring 
Type of 
surgery 
Mean(a) Median 
  Estimate Std. 
Error 
95%  
Confidence Interval 
Estimate Std. 
Error 
95%  
Confidence Interval 
      Lower 
 Bound 
Upper  
Bound 
    Lower  
Bound 
Upper  
Bound 
Gross total 
removal 
12,694 ,521 11,673 13,715 12,500 ,673 11,182 13,818 
Subtotal 
removal 
7,508 ,998 5,551 9,464 6,000 ,849 4,337 7,663 
Overall 11,966 ,484 11,018 12,915 11,000 ,552 9,917 12,083 
 
For determining the role of age as a 
prognostic factor all the 266 patients were 
split in 2 groups: one under 65 years old 
and another one above 65. The first group 
contained 213 patients and the second one 
53 patients. The survival rate had been 
observed at 12, 18 and 24 months. In all 
situations a statistic association has been 
found between age and survival. The 
younger patients had a better survival than 
the ones over the age of 65 (Table 6,7 and 
8).  Meanwhile in the under 65 years of age 
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group the mean survival  was of 9,3 months 
(with lower bound at 8,802 and the upper 
bound at 9,797), in the group over 65 the 
mean survival was of 7,1 months with the 
lower bound at 6,113 and the upper bound 
at 8,228. The difference was more 
significant at the 18 months monitoring, 
with a difference of mean survival of 4 
months in favour of the younger group. At 
the 24 months monitoring the difference 
was also significant, with a mean of 4,8 
months in favour of the patient younger 
than 65. 
 
TABLES 6, 7 AND 8 
Mean and median for survival time at 12,18 and 24 months 
Age Mean(a) Median 
  Estimate Std. 
Error 
95% Confidence 
Interval 
Estimate Std. 
Error 
95% Confidence 
Interval 
      Lower 
Bound 
Upper 
Bound 
    Lower 
Bound 
Upper Bound 
<65 years 9,300 ,254 8,802 9,797 . . . . 
=>65 years 7,171 ,539 6,113 8,228 8,000 1,211 5,626 10,374 
Overall 8,875 ,236 8,413 9,337 11,000 . . . 
 
Age Mean(a) Median 
  Estimate Std. 
Error 
95% Confidence 
Interval 
Estimate Std. 
Error 
95% Confidence 
Interval 
      Lower 
Bound 
Upper 
Bound 
    Lower 
Bound 
Upper 
Bound 
<65 years 11,714 ,420 10,891 12,537 12,500 ,715 11,098 13,902 
=>65 years 7,750 ,825 6,133 9,367 6,500 1,366 3,823 9,177 
Overall 10,966 ,388 10,205 11,727 11,000 ,552 9,917 12,083 
 
Age Mean(a) Median 
  Estimate Std. 
Error 
95%  
Confidence Interval 
Estimate Std. 
Error 
95%  
Confidence Interval 
      Lower  
Bound 
Upper  
Bound 
    Lower  
Bound 
Upper  
Bound 
<65 years 12,882 ,535 11,833 13,930 12,500 ,715 11,098 13,902 
=>65 years 8,029 ,922 6,221 9,837 6,500 1,366 3,823 9,177 
Overall 11,966 ,484 11,018 12,915 11,000 ,552 9,917 12,083 
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Figure 11 Survival graphic at 12, 18 and 24 months depending on age 
 
Regarding de pathological findings, there 
is no statistical significant difference at 12 
and 18 months monitoring (p=0.09 
respectively p=0,122). For survival at 24 
months, the survival mean for glioblastoma 
multiforme diagnosed patients was of 11,2 
months, for the ones having anaplastic 
astrocytoma was of 11,9 months. Patients 
with malignant oligodendrogliomas 
survived approximately for 16,1 months 
(with a confidence interval of 95% between 
12,6 and 19,6) and the ones with malignant 
ependymoma for 17,1 months  (p=0.031). 
(Table 9)  
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Figure 12 Survival functions  depending on the pathological findings at 12, 18 and 24 hours monitoring 
 
TABLE 9 
Mean and median survival time depending on pathological findings at 24 months 
monitoring 
Pathological 
diagnostic 
Mean(a) Median 
  Estimate Std. 
Error 
95%  
Confidence Interval 
Estimate Std. 
Error 
95%  
Confidence Interval 
      Lower  
Bound 
Upper  
Bound 
    Lower  
Bound 
Upper  
Bound 
Anaplastic astocytoma 11,946 ,786 10,406 13,486 12,000 ,645 10,736 13,264 
Anaplastic 
ependymoma 
17,100 3,889 9,477 24,723 . . . . 
Glioblastoma 
multiforme 
11,205 ,632 9,966 12,444 10,000 ,715 8,598 11,402 
Anaplastic 
oligodendrogliomas 
16,167 1,795 12,648 19,685 17,500 2,635 12,335 22,665 
Overall 11,966 ,484 11,018 12,915 11,000 ,552 9,917 12,083 
 
Discussions 
The treatment of patients with high-
grade gliomas remains a challenge for 
modern therapy. Clear treatment guidelines 
regarding the extent of surgery, derived 
from randomized prospective studies in the 
literature do not exist, and there are some 
controversy regarding the best treatment for 
malignant brain tumours. The gold 
standard for high-grade gliomas includes 
combination of surgery, radiotherapy, and 
chemotherapy. 
High grade gliomas are widely 
infiltrative , fact them makes quite 
impossible to completely resect, even in 
cases of hemispherectomy, procedure that 
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was pioneered by Walter Dandy in 1928[6]. 
In order to achieve the cure of this highly 
malignant tumours some other authors 
have been presented their results with 
hemispherectomy, although associated with 
a poor postoperative survival rate, but also 
with a recurrence of tumours in an interval 
of less than two years [ 3,6,12,23]. Despite 
of impressive progress of the last two 
decades in terms of neuroimagistic 
diagnostic, despite of the new inraoperative 
tools namely neuronavigation, 
ultrasonography, awake neurosurgery or 
introperative MRI,  the  nowadays 
neurosurgical results in malignant gliomas 
are still disappointing in terms of long term 
survival [17].  
Usually tumour recurrence occurs close 
to the resection margin, were the cell 
density is increased. Outside of this region 
the cell density drops sharply as the distance 
from the resection cavity increases, an 
argument in favour of a wider resection 
margin which presumably could delay 
recurrence[1, 3]. 
In a review of literature Ryken et al. [24] 
selected thirty qualitative papers, 10 
prospective studies and twenty retrospective 
studies. Five of the prospective studies 
provided Class II data [2, 15, 30, 31, 35] 
and one of the 20 retrospective studies 
provided Class II data [15]. All, but one of 
these better quality studies support extent 
of resection as a factor in improving 
survival in newly diagnosed adult patients 
with malignant glioma. Of these only the 
study of Levin published in 1985[17] failed 
to support extent of resection for 
glioblastoma, but did demonstrate a survival 
advantage in cases of anaplastic astrocytoma. 
Of the remaining retrospective papers 
reviewed, all provided Class III data. 
Fourteen studies of the nineteen provided 
data, which supported the concept of 
cytoreductive surgery in the initial 
management of malignant glioma. Some of 
these reviewed studies are presented in 
summary. 
In 2003, Metcalfe and Grant provided an 
update on the Cochrane report of 2000 on 
biopsy versus resection for malignant 
glioma [19]. After a search of over 2,100 
documents, the authors failed to locate 
enough randomized data for analysis; 
therefore no conclusion could be drawn. A 
recommendation was made calling for 
randomized prospective study of this 
important issue. 
Stummer et al.[31] describe a 
prospective study evaluating the extent of 
resection and its influence on survival 
employing 5-aminolevulinic acid, a 
fluorescent marker . Focused on the 
novelty to the radical resection of gliomas 
using a fluorescent marker to aid in 
desection decision, the study underlines in  
subsidiary the advantage of gross total 
removal over de subtotal resection in terms 
of survival in multivariate analysis. 
 In the same review of Ryken [24],  
Bricolo et al. are mentioned with a 
preliminary report of a prospective data 
collection on patients with presumed 
malignant glioma subjected to an aggressive 
surgical strategy and assessed 
postoperatively with CT scanning placing 
them either in a gross total resection or 
subtotal resection (10–15% remaining 
enhancement) group. While no statistical 
analysis is provided the authors report at 
60% 1 year survival for their gross total 
resection group versus only 24% in the 
subtotal resection group. 
Lacroix et al. [17] found that surgical 
resection of 98% or more of the contrast-
enhancing tumour volume is an 
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independent variable associated with longer 
survival times in patients with glioblastoma 
multiforme. As a consequence their 
recommendation is that gross-total 
resection should be performed whenever 
possible for these patients, yet not at the 
expense of neurologic function or surgical 
complications.  
In the study of Nitta et al. of 101 patients 
with malignant glioma including 68 patients 
with GBM and 32 with anaplastic 
astrocytoma who underwent operative 
procedures followed by a uniform 
radiotherapy and chemotherapy regimen 
[22], the authors found that in the 
glioblastoma group the patients undergoing 
gross total resection as judged by 
postoperative CT survived significantly 
longer than patients undergoing either a 
partial resection (less than 75%) or subtotal 
resection (75—less than 100%). They 
suggested that gross total excision might aid 
in the adjuvant therapy following surgical 
intervention. 
Devaux et al.[7] in a retrospective study 
of 218 patients with newly diagnosed 
malignant glioma including 164 patients 
with Grade IV tumours and 54 patients 
with Grade III tumours found that using a 
detailed surgical approach designed to 
achieve volumetric resection was of benefit 
in prolonging survival in Grade IV patients 
even after adjustment for no clinical 
prognostic factors. 
As a result, it follows that the majority of 
the reviewed data supports maximal 
cytoreductive surgery. 
In our retrospective study of 266 cases 
that met inclusion criteria for statistical 
monitoring at 12, 18 and 24 months, the 
obtained data also supported maximal 
cytoreductive surgery in order to prolong 
survival of patients with malignant gliomas. 
In this study only GTR with STR are 
compared, based on the senior author 
intraoperative impression and confirmed on 
immediate postoperative enhanced CT scan 
or MRI. Based on postoperative imaging we 
consider STR any contrasted remnants 
visible on more than two adjacent slices 
from the initial volume of tumour. At 12 
months monitoring, the survival was 
around 9,2 months in patients with GTR, 
with a confidence interval between 8,7 and 
9,7, meanwhile in the STR group the 
survival mean was of 6,4 months, with a 
confidence interval of 95% from 5,2 to 7,7. 
Similar findings are found at 18 months 
interval monitoring, the survival mean for 
patients with GTR was of 11.5 months 
(with a confidence interval of 95% from 
10,7 to 12,4), significantly higher than 
survival rate for STR group (7,1 months, 
with confidence from 5,5 to 8,7, p<0,005). 
The survival monitoring at 24 months has 
also highlighted a significant difference of 
survival between GTR and STR groups 
(p< 0,005). The survival mean at GTR 
group was of 12,6 months, comparing to 7,5 
months for the STR group. As it is shown, 
the difference increases from almost three 
months on the first period of monitoring 
(12 months) up to 5 months in the 24 
months monitoring period. A median 
survival difference from three months up to 
five months between GTR and STR 
represents findings that are consistently in 
favour of maximal cytoreduction, at least in 
our opinion. Based on our data we consider 
our study a class III recommendation.  
Failure to demonstrate prolonged 
survival with Class I data should not stop 
physicians from considering surgical 
resection thanks to the numerous other 
benefits of tumour removal. 
The obvious benefits from glioma 
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resection are symptomatic relief from mass 
effect and obstructed cerebrospinal fluid. 
The tumoral mass produces compression of 
neural pathways and distortion of brain 
structure that contribute to both general 
symptoms and focal deficits and explain the 
neurological improvement  following 
surgical resection. After surgery there are 
some global symptoms (headache, nausea, 
vomiting, general malaise) that show 
dramatic improvement (11). The partial 
reversal of neurological deficit is due to the 
relief of local compression (36). 
Dexamethasone  in dose of 16 mg per day 
has been proved an useful indicator of  
potential neurological improvement after 
glioma resection. Patients who show 
improved functional status after steroid 
administration will be the one with 
improvement  in quality of life after 
aggressive surgical resection, provided that 
there is low postoperative morbidity (20). 
A number of authors observed that 
partial tumour resection is associated with 
greater risk of postoperative neurological 
worsening than either radical excision or 
stereotaxic biopsy [5,14,25,29]. In the series 
of Ciric et al [5] 97% of patients with gross 
total or nearly gross total resection had 
improved or stable postoperative 
neurological status; in contrast, 
postoperative neurological worsening 
occurred in 40% of patients with partial 
resection. In two other series Fadul et al 
[8], Vecht et al, [34] no significant 
difference was found in the incidence of 
neurological worsening following gross 
total resection compared to limited 
resection. These data from various studies 
suggest that radical tumour resection is 
associated with no greater or perhaps less 
risk of neurological compromise than with 
partial resection. 
In our experience we also could 
document a global improvement of 
neurological status in more than 85% of the 
GTR operated cases, with a less than 10% 
rate of neurological complications, and a 
mortality rate below 4%, large majority of 
them being patients with more than 70 
years of age.  
Related to age there are some studies 
that provide useful data regarding elderly 
patients, namely those over 65 [4,35]. In 
the latest study of Chaichana (2010)[4] they 
found that patients who underwent surgical 
resection had median survival of 5.7 
months, while patients who underwent 
needle biopsy without resection had 
median survival of 4.0 months. Although 
modest in absolute terms, older patients did 
have significantly prolonged survival with 
aggressive resection as compared to needle 
biopsy, without an increase in surgical 
morbidity or mortality. Their study 
demonstrates that older patients undergoing 
aggressive resection did not have an 
increase in surgical morbidity, and had 
prolonged survival as compared to matched 
older patients undergoing needle biopsy. 
Older patients, as with younger patients, 
may therefore benefit from aggressive 
surgical resection, and aggressive resection 
should be considered for older patients who 
present with GBM. 
We are also in favour of aggressive 
surgery in patients older than 65, despite 
the fact that their median of survival is 
significantly lower than that of the younger 
patients. Meanwhile in the under 65 years 
old group the mean survival was 9,3 
months (with lower bound at 8,802 and the 
upper bound at 9,797), in the group over 65 
the mean survival was 7,1 months with the 
lower bound at 6,113 and the upper bound 
at 8,228. The difference was more 
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significant at the 18 months monitoring, 
with a difference of mean survival of 4 
months in favour of the younger group 
(11,7 vs. 7,7 months), difference which is 
also maintained at the 24 months 
monitoring (12,8 versus 8,0 month). 
Despite the fact that we compare only 
patients with GTR and STR, without 
Needle biopsy sampling, and considering 
the recent provided data from the 
Chaichana's study, we can conclude that 
maximal cytoreduction surgery is 
recommendable in the elderly patients, 
mentioning also the fact that the mortality 
is higher in the group of patient over 65.  
The mechanical cytoreduction of the 
mass also obtains time for other therapeutic 
interventions (radiotherapy, chemotherapy, 
and immunotherapy). The reduced tumour 
burden has been shown to have a beneficial 
effect on cerebral blood flow and 
metabolism even at sites in the brain distant 
from tumour resection.  
One hundred grams of tumour mass is 
considered lethal for the average adult. 
Along with surrounding edema, the 
tumoral mass accounts for 10% of the 
intracranial volume. For the neurologic 
symptoms to appear it generally takes 30 to 
60 g of tumour or 3 to 6x1010 cell. 1 g of 
tumoral mass or 1x109 cell is thought to be 
left after a total resection of the gadolinium 
enhancing regions on magnetic resonance 
imaging. The adjuvant therapy of malignant 
glioma also contributes to tumoral 
reduction. While radiotherapy kills two logs 
of cell, chemotherapeutic regimens are 
thought to kill one to two logs of cell. The 
body’s immune mechanisms are believed to 
suppress tumour burdens less than 1x105  
cells. Despite these promising assertion , 
malignant glioma remains for the vast 
majority of patients an incurable disease 
(16). 
The efficacy of adjuvant therapy is 
increased when the tumour load is lower. A 
higher glioblastoma load increased 
chemotherapy resistance as it was 
demonstrated in an in vivo study. In order 
to achieve the same effect, a 4-fold increase 
in the glioblastoma load requires a 2-fold 
increase in the BCNU concentration (21). 
Other argument in favour of open 
surgery is the accuracy of histological 
diagnosis, which is dependent on the size of 
the tissue sample. As a result of limited 
tissue samples, the stereotactic biopsy is 
associated with false negatives, with is 
estimated to be around 10% (27). A 
discrepancy rate of 38% between biopsy and 
subsequently resected specimens in 81 
patients was reported by Jackson et al (13). 
In 26% of cases, this discrepancy was found 
to affect the treatment. For the 38% of cases 
the prognosis was altered. 
Concerning the pathological findings, 
not surprisingly in our study there is no 
statistical significant difference at 12 and 18 
months monitoring (p=0.09 respectively 
p=0,122). For survival at 24 months, the 
survival mean for glioblastoma multiforme 
diagnosed patients was 11,2 months, for the 
ones having anaplastic astrocytoma was 11,9 
months. Patients with malignant 
oligodendrogliomas survived for 
approximately 16,1 months (with a 
confidence interval of 95% between 12,6 
and 19,6) and the ones with malignant 
ependymoma 17,1 (p=0.031). 
Finally surgical resection of large sample 
of tumour may serve as an aid in research. 
The collection of large human tumour 
samples allows for comprehensive 
molecular analysis and fingerprinting of 
each tumour [9,33] , which in turn may 
lead to the development of individually-
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tailored molecular therapies. Increasing 
evidence suggests that tumors of the central 
nervous system are derived from 
proliferatively active neural stem cells 
residing in defined neuropoietic niches of 
the adult brain. These cancer stem cells, 
also identified in other tumors, provide a 
reservoir of cells with self-renewal 
capabilities, can maintain the tumor by 
generating differentiated non-stem tumor 
cells and are responsible for recurrences 
after ablative neurosurgical therapy and 
chemoradiotherapy. 
The only way to successfully control 
recurrent malignant gliomas and even hope 
for a cure in the future is by combining 
standard chemotherapy with 
immunotherapy. Despite the apparent 
improvements of current  treatments, it 
should be realized that the characteristic 
brain tumor niche may provide recurrent 
gliomas an “escape mechanism” from 
anticancer treatments. Thus, the use of 
targeted molecular therapy drugs may 
effectively  inhibit or at least slow down 
cancer stem cell proliferation and stop the 
brain microenvironment from allowing 
furtive invasion and proliferation of highly 
aggressive malignant gliomas[9]. Only 
through further understanding of the 
biology of gliomas can we hope to find a 
cure in the future. 
Conclusion 
The review of the literature suggests that 
gross total resections for patients with 
malignant gliomas can improve both 
survival and quality of life. Different studies 
show that early and long term postoperative 
outcome after radical surgical resection are 
better than the results of either partial 
resection or simple biopsy, in terms of 
neurological status and duration of survival. 
Similarly, reoperation for recurrence of 
glioma offers reasonable extension of 
quality survival.  
Our study provides a new argument in 
favour of gross total removal. We have 
shown that radical surgery improves the 
overall survival and total resection should 
be considered whenever possible. An 
aggressive cytoreduction is recommendable 
also in patients over the age of 65. Total 
removal for patient with tumour recurrence 
does not change statistically significant the 
global survival comparing to partial removal 
but the quality of life sure benefits from it, 
by decreasing the intracranial pressure.  
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